86518-09-4Relevant articles and documents
BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
-
Page/Page column 398, (2017/12/05)
This invention provides a Degronimer that has an E3 Ubiquitin Ligase targeting moiety (Degron) that can be linked to a Targeting Ligand for a bromodomain protein selected for in vivo degradation to achieve a therapeutic effect, and methods of use and compositions thereof as well as methods for their preparation.
SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
-
Page/Page column 278, (2017/12/01)
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
-
Page/Page column 434, (2017/12/01)
This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.
HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
-
Page/Page column 332, (2017/12/02)
This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ("Degrons"), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
-
Page/Page column 273, (2017/12/05)
This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
LITHIATION DE FURO- ET PYRROLOPYRIDINES SUBSTITUEES SUR LEUR POSITION 4
Bisagni, E.,Hung, N. Chi,Lhoste, J. M.
, p. 1777 - 1782 (2007/10/02)
Lithiation of the title compounds using t-butyl lithium occurs at c-2 of the five-membered ring.